SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- Biosite Incorporated
(Nasdaq: BSTE) and Fisher HealthCare, a unit of Fisher Scientific
International Inc. (NYSE: FSH), today announced they have renewed their
distribution relationship. The renewal becomes effective on January 1, 2006.
The new agreement extends the companies' relationship, which commenced in
1991, through 2008 and positions Fisher HealthCare as the primary distributor
of Biosite's complete line of innovative diagnostic products to U.S.
hospitals. In addition, Fisher will continue to serve as a distributor of
Biosite products to U.S. physician offices.
"This agreement provides Biosite and our customers with dual advantages,"
said Kim Blickenstaff, Biosite's chairman and chief executive officer. "Not
only does it provide us with a powerful sales force in the healthcare markets
we serve, but it also allows us to take advantage of Fisher HealthCare's
logistical distribution expertise, ensuring high quality access for our U.S.
customers."
About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company commercializing
proteomics discoveries for the advancement of medical diagnosis. The
Company's products contribute to improvements in medical care by aiding
physicians in the diagnosis of critical diseases and health conditions.
Biosite's Triage(R) rapid diagnostics are used in approximately 50 percent of
U.S. hospitals and in more than 50 international markets. Information on
Biosite can be found at http://www.biosite.com.
Fisher Scientific: A World Leader in Serving Science
Fisher Scientific International Inc. (NYSE: FSH) is a leading provider of
products and services to the scientific community. Fisher facilitates
discovery by supplying researchers and clinicians in labs around the world
with the tools they need. Fisher serves pharmaceutical and biotech companies;
colleges and universities; medical-research institutions; hospitals;
reference, quality-control, process-control and R&D labs in various
industries; as well as government agencies. From biochemicals, cell-culture
media and proprietary RNAi technology to rapid-diagnostic tests, safety
products and other consumable supplies, Fisher provides more than 600,000
products and services. This broad offering, combined with Fisher's globally
integrated supply chain and unmatched sales and marketing presence, helps make
the Company's 350,000 customers more efficient and effective at what they do.
Founded in 1902, Fisher Scientific is a FORTUNE 500 company and is a
component of the S&P 500 Index. Fisher has approximately 17,500 employees
worldwide, and its annual revenues are expected to exceed $5.5 billion in
2005. Fisher Scientific is a company committed to high standards and
delivering on its promises -- to customers, shareholders and employees alike.
Additional information about Fisher is available on the company's Web site at
http://www.fisherscientific.com.
About Fisher HealthCare
Fisher HealthCare is a leading supplier of diagnostic tests, equipment,
chemicals, and other products used by national laboratory networks,
independent clinical laboratories, hospitals, and physicians' offices.
Information about Fisher HealthCare and its products is available on the
company's Web site at http://www.fishersci.com.
Except for the historical information presented herein, matters discussed
in this press release are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by such
statements. Statements that are not historical facts, including but not
limited to statements that are preceded by, followed by, or that include the
words "will"; "believes"; "should"; "intends"; "anticipates"; "plans";
"expects"; "estimates"; or similar statements are forward-looking statements.
Risks include Fisher's ability to continue to distribute Biosite products in
the U.S. hospital and physician office markets, risks and expenses associated
with litigation, contract disputes, patent conflicts, product recalls,
manufacturing constraints, backlog, delays or inefficiencies, shipment
problems, seasonal customer demand, the timing of significant orders, changes
in reimbursement policies, regulatory changes, competitive pressures on
average selling prices, and the other risks detailed in Biosite's most recent
Annual Report on Form 10-K, as amended, and other SEC filings. In addition,
under certain specific circumstances either party may elect to terminate this
agreement prior to its scheduled expiration. Biosite disclaims, any intent or
obligation to update these forward-looking statements. Copies of Biosite's
public disclosure filings are available from its investor relations
department.
Biosite(R) and Triage(R) are registered trademarks of Biosite
Incorporated. New Dimensions in Diagnosis(TM) and the Company's logo are
trademarks of Biosite Incorporated.
SOURCE Biosite Incorporated
 back to top
Related links:
http://www.biosite.com
Company News On-Call:
http://www.prnewswire.com/comp/116737.html
CONTACT:
Nadine Padilla, VP, Corporate & Investor
Relations, Biosite Incorporated, +1-858-455-4808 ext. 3187,
npadilla@biosite.com
|
